Sarepta Therapeutics announced significant progress on its SRP-1003 siRNA candidate for Myotonic Dystrophy type 1 (DM1), activating a $100 million milestone payment to partner Arrowhead Pharmaceuticals. To fund this milestone, Sarepta sold 9.2 million Arrowhead shares and transferred an additional 2.6 million shares. This financial maneuver was part of a broader strategic restructuring, including a 36% workforce reduction to prioritize pipeline sustainability. Positive clinical developments and upcoming data releases for SRP-1003 and related programs signal continued commitment to RNA interference therapeutics in neuromuscular diseases.